xiaodong lu
Emory University
Atlanta, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Emory University
Atlanta, United States
Review Editor
Cancer Molecular Targets and Therapeutics
University of Notre Dame
Notre Dame, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Xijing Hospital, Air Force Medical University
Xi’an, China
Review Editor
Cancer Molecular Targets and Therapeutics
University of Texas MD Anderson Cancer Center
Houston, United States
Review Editor
Cancer Molecular Targets and Therapeutics
City of Hope National Medical Center
Duarte, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Beijing Hospital, Peking University
Beijing, China
Review Editor
Cancer Molecular Targets and Therapeutics
University of SĂŁo Paulo
SĂŁo Paulo, Brazil
Review Editor
Cancer Molecular Targets and Therapeutics
Genentech Inc.
San Francisco, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Goodman Cancer Research Centre, McGill University
Montreal, Canada
Review Editor
Cancer Molecular Targets and Therapeutics
Virginia Commonwealth University
Richmond, United States
Review Editor
Cancer Molecular Targets and Therapeutics
CONICET - Universidad de Buenos Aires. Instituto de Investigaciones Biomédicas (INBIOMED)
Buenos Aires, Argentina
Review Editor
Cancer Molecular Targets and Therapeutics
Karolinska Institutet (KI)
Solna, Sweden
Review Editor
Cancer Molecular Targets and Therapeutics
Department of Pharmacy and Pharmaceutical Sciences, University of Bari Aldo Moro
Bari, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Perlmutter Cancer Center, Langone Medical Center, New York University
New York, United States
Review Editor
Cancer Molecular Targets and Therapeutics
University of Ferrara
Ferrara, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Department of Genetics and Biochemistry, Clemson University
Clemson, United States
Review Editor
Cancer Molecular Targets and Therapeutics